Sep 30, 2022 11:00 JST
Source: Olympus
|
|
Olympus Launches THUNDERBEAT Energy Device for Open Surgery
TOKYO and CENTER VALLEY, PA., Sep 30, 2022 - (JCN Newswire) - Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer, and more fulfilling, today announced the release of the THUNDERBEAT(TM) Open Fine Jaw Type X surgical energy devices for open surgery. With a new thermal shield, the THUNDERBEAT Open Fine Jaw Type X surgical energy device is designed to support safer procedures.[i] The device is available commercially in Japan. The commercial launch of the product in Europe, the U.S., and South Korea is expected in October 2022, with continued launches in other countries and regions following.
This device is part of Olympus' THUNDERBEAT portfolio of hybrid energy devices that deliver both ultrasonic and bipolar energy simultaneously for tissue management, including hemostatic cutting and dissection, in laparoscopic surgery and open surgery. The THUNDERBEAT hybrid devices eliminate the need for multiple instruments during the surgery, contributing to efficiency in the operating room and reduced operation time.[ii]
"This latest addition to our differentiated THUNDERBEAT line of products continues to deliver on Olympus' commitment to offering hospitals a full portfolio of Advanced Energy devices providing best-in-class functionality for numerous procedures and specialties in minimally invasive and open surgery," said Phil Roy, Global Vice President and General Manager of the Surgical Devices Business Unit.
The THUNDERBEAT(TM) Open Fine Jaw Type X device is designed for open surgical procedures that require delicate and fine tissue dissection, such as in thyroidectomy or radical neck dissection. The new thermal shield improves the thermal profile on the grasping surface, which reduces the risk of unintended heat damage to nearby tissue, nerves and other structures.[i] The jaw design maintains a finely curved tip for precise dissection and enhanced visibility during use.[i]
- New Thermal Shield Supports Safer Procedures The newly developed thermal shield at the distal tip slows heat transfer from the probe to the exterior surface of the jaw and reduces the risk of unintended heat damage to surrounding tissue and vessels.[i]
- Fine Shape of Distal Tip Supports Precise Procedures The slim shape of the distal tip supports precise tissue management capabilities including fine dissection and firm grasping force, cutting and sealing to the tip of the device, and blunt dissection.[i]
- Simultaneous Output of Two Energies Enables a Variety of Operations with One Device Delivering simultaneous bipolar and ultrasonic energy enables fast, hemostatic cutting, easy dissection, and reliable vessel sealing and division. A separate advanced bipolar[i] function enables vessel sealing and spot coagulation without cutting, when desired.
The THUNDERBEAT(TM) Open Fine Jaw Type X device is a single use hybrid ultrasonic and bipolar electrosurgical instrument intended for use in open surgery. This device should not be used for tubal sterilization or tubal coagulation for sterilization procedures. Use with caution in patients with electronic implants, such as a cardiac pacemaker, or nerve simulators, to avoid possible hazard to patients due to interference. Before use, thoroughly review the product manual and use the equipment as instructed.
The THUNDERBEAT Open Fine Jaw Type X device is manufactured by Olympus Medical Systems Corporation.
About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people's lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with its early contributions to the development of the polypectomy snare, Olympus' Therapeutic Solutions portfolio has grown to include a wide range of medical devices to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.
[i] Data on file with Olympus as of May 11, 2020 [ii] Data on file with Olympus as of June 26, 2015
Media Contacts Natsuki Inoue - natsuki.inoue@olympus.com Jessica Lee - jessica.yy.lee@fleishman.com
Olympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLYs] https://www.olympus-global.com
Source: Olympus Sectors: BioTech, Healthcare & Pharm, MedTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
|
Latest Release
JCB Launches Red Guahan Shopping Mall Shuttle Free Ride Promotion in Guam Dec 26, 2024 12:00 JST
| Mazda Production and Sales Results for November 2024 Dec 26, 2024 11:46 JST
| MHI Conducts Nighttime and Long-Distance Highway Demonstration Testing of Unmanned Aerial Vehicle Currently Under Development Dec 26, 2024 09:47 JST
| Hitachi delivers a turnkey rail solution for Ho Chi Minh City's first urban railway Line 1 in Vietnam Dec 24, 2024 13:19 JST
| Nissan and Honda sign MOU to consider business integration Dec 24, 2024 11:18 JST
| Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year Dec 24, 2024 11:00 JST
| Nissan, Honda, and Mitsubishi Motors sign MOU on collaborative considerations Dec 24, 2024 10:54 JST
| GAC Honda Begins Operation of New Energy Vehicle (NEV) Production Factory in Guangzhou, China Dec 24, 2024 10:23 JST
| Sarawak Premier Makes Inaugural Visit to Mitsubishi Power's Takasago Hydrogen Park Dec 24, 2024 10:10 JST
| Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases Dec 23, 2024 17:22 JST
| Fujitsu drives chemical industry logistics DX with participation in joint logistics demonstration Dec 23, 2024 13:30 JST
| Mitsubishi Motors Cumulative Production Reaches One Million Units in Indonesia Dec 20, 2024 17:35 JST
| Contract Renewed on Operation and Maintenance (O&M) Services for APM System at Washington Dulles International Airport Dec 20, 2024 17:24 JST
| Toyota Launches Alphard and Vellfire PHEV Models in Japan Dec 20, 2024 15:38 JST
| 6G Begins! Embarking on a New Journey of Global Interoperable Standards Dec 19, 2024 16:50 JST
| MI LNG Company to Change Corporate Name to MILES Dec 19, 2024 13:49 JST
| Two Honda 0 Series Prototype Models to Premiere at CES 2025 Dec 19, 2024 12:30 JST
| Honda Presents World Premiere of Honda S+ Shift, Next-generation e:HEV Technology Dec 19, 2024 12:13 JST
| NEC Completes new Asia Pacific submarine cable Dec 19, 2024 12:02 JST
| Enablement of JCB Contactless Payment at All NJ TRANSIT Contactless Bus and Light Rail Validators in New Jersey, New York, and Pennsylvania Dec 19, 2024 12:00 JST
|
More Latest Release >>
|